ArticleFrontiers in endocrinology2020
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity.
Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Effects of short-term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial.Obesity (Silver Spring, Md.) · 2023Trial
- Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis.Nutrients · 2023Trial
- Liver Fat Is Associated With Elevated FGF21 in Youth With Obesity but Without MASLD.Pediatric obesity · 2026Article
- The association between hepatic steatosis, vitamin D status, and insulin resistance in adolescents with obesity.Obesity pillars · 2025Article
- Pediatric Obesity: Complications and Current Day Management.Life (Basel, Switzerland) · 2023Review
- Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.International journal of biological sciences · 2023Review
- Risk assessment with gut microbiome and metabolite markers in NAFLD development.Science translational medicine · 2022Article
- Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.Oxidative medicine and cellular longevity · 2022Review
- Circulating microRNAs Are Associated With Metabolic Markers in Adolescents With Hepatosteatosis.Frontiers in endocrinology · 2022Article
- The Saga of Endocrine FGFs.Cells · 2021Review
- Circulating miRNA Signatures Associated with Insulin Resistance in Adolescents with Obesity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.